Patent Grant
10231830
This document provides leaflets made out of Kidney Capsule Material.
Heart valve surgery can be used to repair or replace diseased heart valves. For example, heart valve replacement may be indicated when there is a narrowing of the native heart valve, commonly referred to as stenosis, or when the native valve leaks or regurgitates. The repair or replacement of diseased heart valves can include, for example, the introduction of a prosthetic heart valve that includes biological tissue heterologous to the patient (e.g., a heterograft or xenograft). A common biological tissue used to make prosthetic heart valves is pericardial tissue, typically bovine or porcine.
Prosthetic heart valves provided herein use kidney capsule tissue as the leaflet material. The kidney capsule, also known as the renal capsule, is a tough fibrous layer surrounding the renal cortex of the kidney and covered in a thick layer of perinephric adipose tissue. It provides some protection from trauma and damage. As used herein, the term “kidney capsule” does not include the renal cortex or the perinephric adipose tissue.
In Example 1, a prosthetic heart valve can include a plurality of leaflets secured together and retained within the expandable tubular member, where each leaflet includes cross-linked kidney capsule tissue.
In Example 2, a prosthetic heart valve of Example 1, where the small intestine submucosa tissue includes multiple layers of kidney capsule tissue.
In Example 3, a prosthetic heart valve of Example 1 or Example 2, wherein the leaflet has a total thickness of between 50 microns and 0.33 mm.
In Example 5, a prosthetic heart valve of one of Examples 1-4, where the kidney capsule tissue has a moisture content of between 73% and 94%.
In Example 6, a prosthetic heart valve of one of Examples 1-5, where the kidney capsule tissue has an ultimate tensile strength of between 3.6 MPa and 8.0 MPa.
In Example 7, a prosthetic heart valve of one of Examples 1-6, where the kidney capsule tissue has a modulus of between 20 and 40.
In Example 8, a prosthetic heart valve of one of Examples 1-7, where the kidney capsule tissue has a percent elongation at 1 MPa of between 5% and 10%.
In Example 9, a prosthetic heart valve of one of Examples 1-8, where the kidney capsule tissue has an elongation to break at between 50% and 75%.
In Example 10, a prosthetic heart valve of one of Examples 1-9, where the tissue bi-axially oriented.
In Example 11, a prosthetic heart valve of one of Examples 1-10, where tissue is cross-linked by submerging the kidney capsule tissue in a solution of between 0.1 and 1.5 wt % glutaraldehyde for at least 10 minutes.
In Example 12, a prosthetic heart valve of one of Examples 1-10, where the tissue is cross-linked by submerging the kidney capsule tissue in a solution of between 0.5 and 1.0 wt % glutaraldehyde for at least 30 minutes.
In Example 13, a prosthetic heart valve of one of Examples 1-10, where the tissue is cross-linked by submerging the kidney capsule tissue in a solution of between 0.5 and 0.7 wt % glutaraldehyde for at least 2 hours.
In Example 14, a prosthetic heart valve of one of Examples 1-13, where the leaflets consist of the cross-linked kidney capsule tissue.
In Example 15, a method of forming a kidney capsule leaflet includes: (a) obtaining kidney capsule; (b) cutting and stacking multiple layers of the kidney capsule into a substantially planar patch of kidney capsule tissue having a thickness of at least 50 microns; (c) contacting the kidney capsule tissue with a chemical cross-linker for at least 10 minutes to cross-link the patch; and (e) cutting out a leaflet from the patch, the leaflet comprising a body portion and two sleeve portions.
In Example 16, the method of Example 15 where the chemical cross-linker is glutaraldehyde.
In Example 17, the method of Example 16 where the kidney capsule tissue is submerged in a solution comprises between 0.1 and 1.5 wt % glutaradehyde to cross-link the kidney capsule.
In Example 18, the method of Example 16 where the tissue is cross-linked by submerging the kidney capsule tissue in a solution of between 0.5 and 1.0 wt % glutaraldehyde for at least 30 minutes.
In Example 19, the method of Example 16 where the tissue is cross-linked by submerging the kidney capsule tissue in a solution of between 0.5 and 0.7 wt % glutaraldehyde for at least 2 hours.
The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
Like reference symbols in the various drawings indicate like elements.
Prosthetic heart valves provided herein include cross-linked kidney capsule tissue leaflets. Prosthetic heart valves have typically used bovine or porcine pericardium tissue leaflets, but cross-linked kidney capsule tissue can provide a thinner wall thickness while providing a sufficient ultimate tensile strength and other mechanical properties.
Table I showcases the tensile and thickness properties of two different types of tissue: Porcine kidney capsule and bovine pericardium. Both types of tissue are fixed, or chemically crosslinked, in glutaraldehyde. Fixation bestows unique material properties to tissue subjected to the treatment. By looking at the average values for select outputs, conclusions may be drawn about the differences between the two types of tissue. On average, fixed kidney capsule (FKP) possesses thickness characteristics that are 13% of fixed bovine pericaridum (FBP). Thinner tissue is potentially useful for reducing the profile of implantable devices. On average, FKP possesses an ultimate tensile strength (UTS) that is 39% of FBP. UTS refers to the amount of stress required to fracture a material. On average, FKP possesses a modulus of elasticity that is 33% of FBP.
Modulus of elasticity refers to a material's resistance to being deformed non-permanently (elasticity). Colloquially, this means that FPK is “stretchier” than FBP. On average, FKP possess a strain value at 1 MPa that is 99% of FBP. Strain refers to the amount of deformation that occurs compared to its original size, represented as a percentage. FPK and FBP are functionally identical with regards to this output.
The samples of porcine kidney capsule tissue in Table 1 are for a single sheet of tissue. In some cases, a leaflet provided herein can include one or more layers of cross-linked kidney capsule tissue. For example, a leaflet can include a laminate containing 2, 3, 4, or 5 or more layers of cross-linked kidney capsule tissue. In some cases, a leaflet included herein can have a total thickness of between 50 microns and 0.33 mm, including one or more layers of cross-linked kidney capsule tissue each having a thickness of between 25 and 75 microns. The samples of porcine kidney capsule tissue samples tested had between 73% and 94% moisture content. Unexpectedly, cross-linked porcine kidney capsule tissue shown in Table I has an average of 86% water content, 0.0017″ thick (about 43 microns) has an Ultimate tensile strength of 5.8 MPa. Because the water content of the cross-linked kidney capsule tissue is high compared to bovine pericardium, the kidney capsule tissue can allow for water to be squeezed out to reduce the tissue profile. Additionally, water is a plasticizer, so this could enable the kidney capsule to be more elastic.
In some cases, the cross-liked kidney capsule tissue can be biaxially oriented. In some cases, the kidney capsule tissue can be biaxially tensioned during cross-linking in order to impart the biaxial orientation. In some cases, a sheet of kidney capsule tissue can have a thickness of between 25 microns and 75 microns. In some cases, a leaflet can include one or more layers of kidney capsule tissue to have a total thickness of between 50 microns and 0.33 mm. In some cases, the kidney capsule tissue is bi-axially tensioned by applying a stress load of at least 0.1 N to stretch the kidney capsule tissue along two intersecting axes. In some cases, the kidney capsule tissue is bi-axially tensioned by applying a stress load of between 0.1 N and 2 N to stretch the kidney capsule tissue along two intersecting axes. In some cases, the kidney capsule tissue is bi-axially tensioned by applying a stress load of between 0.5 N and 1 N to stretch the kidney capsule tissue along two intersecting axes. The kidney capsule tissue can be chemically cross-linked while under tension to prevent recoil of the kidney capsule tissue after the tension is released.
After obtaining a kidney and separating the kidney capsule, such as porcine kidney capsule 330, the kidney capsule can be bi-axially oriented and fixed in step 12, which is described below. In step 13, leaflets having a predetermined shape are cut from the fixed kidney capsule tissue, and suitable leaflets selected for use in a prosthetic heart valve, which is described below in connection to
Exemplary processes of fixing kidney capsule tissue 12 is further shown in the flow chart of
In step 22, the kidney capsule tissue is tensioned. For example, a plurality of grippers can be arranged around a patch of kidney capsule tissue placed over a frame and stretched to tension the patch of kidney capsule tissue. In step 23, the tensioned patch of kidney capsule tissue is captured on a frame, such as shown in
In step 25, oriented and fixed kidney capsule tissue can be separated from the frame. In some cases, the oriented and fixed kidney capsule tissue can be cut from the fixed and tensioned kidney capsule tissue while the fixed and tensioned kidney capsule tissue is still secured to the frame. In some cases, the fixed and tensioned kidney capsule tissue can be removed from the frame and subsequently cut. In step 26, the fixed and tensioned kidney capsule tissue is tested to determine if it meets specifications.
In some cases, as shown, prosthetic heart valve 100 includes three kidney capsule leaflets 200. In some cases, prosthetic heart valves provided herein can have any suitable number of kidney capsule leaflets, such as two, three, four, five, or more leaflets. In some cases, kidney capsule leaflets 200 are secured to one another. In some cases, kidney capsule leaflets 200 can be secured to one another by a suture (not shown) or a plurality of sutures. Kidney capsule leaflets 200 can be sutured alongside edges of a body portion of each leaflet. In some cases, prosthetic heart valves provided herein can include a single line of sutures, which can be adapted to minimize leaks, minimize the width of a seam, and/or minimize the profile of a replacement heart valve during a percutaneous insertion. In some cases, prosthetic heart valves provided herein can include multiple lines of sutures.
Referring back to
A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.
This application claims the benefit of U.S. Provisional Application No. 62/253,225, filed Nov. 10, 2015, the contents of which are herein incorporated by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 6409759 | Peredo | Jun 2002 | B1 |
| 20020094573 | Bell et al. | Jul 2002 | A1 |
| 20020103542 | Bilbo et al. | Aug 2002 | A1 |
| 20030229394 | Ogle et al. | Dec 2003 | A1 |
| 20040078090 | Binette et al. | Apr 2004 | A1 |
| 20050143809 | Salahieh et al. | Jun 2005 | A1 |
| 20050222661 | Case et al. | Oct 2005 | A1 |
| 20060159722 | Braithwaite | Jul 2006 | A1 |
| 20060253188 | Case et al. | Nov 2006 | A1 |
| 20070037283 | Patel | Feb 2007 | A1 |
| 20070162103 | Case et al. | Jul 2007 | A1 |
| 20070254005 | Pathak et al. | Nov 2007 | A1 |
| 20090138078 | Paul, Jr. et al. | May 2009 | A1 |
| 20090187241 | Melsheimer | Jul 2009 | A1 |
| 20090216338 | Gingras et al. | Aug 2009 | A1 |
| 20140277416 | Matheny et al. | Sep 2014 | A1 |
| 20160296323 | Wulfman et al. | Oct 2016 | A1 |
| 20170100237 | Anderson-Cunanan et al. | Apr 2017 | A1 |
| 20170100238 | Anderson-Cunanan et al. | Apr 2017 | A1 |
| Number | Date | Country |
|---|---|---|
| 9825549 | Jun 1998 | WO |
| 2017062198 | Apr 2017 | WO |
| 2017062199 | Apr 2017 | WO |
| 2017083183 | May 2017 | WO |
| Entry |
|---|
| Billiar, Kristen L. et al., “Biaxial Mechanical Properties of the Native and glutaraldehyde-Treated Aortic Valve Cusp: Part II—A Structural Constitutive Model,” Journal of Biomechanical Engineering (2000) vol. 122, pp. 327-335. |
| “International Search Report and Written Opinion,” for PCT Application PCT/US2016/053680 dated Dec. 16, 2016 (12 pages). |
| “International Search Report and Written Opinion,” for PCT Application PCT/US2016/053682 dated Jan. 3, 2017 (13 pages). |
| “International Search Report and Written Opinion,” for PCT Application PCT/US2016/060449 dated Feb. 24, 2017 (12 pages). |
| Kelm, J. M. et al., “A Novel Concept for Scaffold-Free Vessel Tissue Engineering: Self-Assembly of Microtissue Building Blocks,” Journal of Biotechnology, 148 (2010): pp. 46-55. |
| “Non-Final Office Action,” for U.S. Appl. No. 15/272,747 dated Oct. 19, 2017 (17 pages). |
| “Non-Final Office Action,” for U.S. Appl. No. 15/272,772 dated Mar. 2, 2018 (17 pages). |
| “Response to Non-Final Office Action,” for U.S. Appl. No. 15/272,747, dated Oct. 19, 2017 and filed with the USPTO Dec. 20, 2017 (9 pages). |
| Cardinal, Kristen O. et al., “Tissue-Engineered Vascular Grafts as In Vitro Blood Vessel mimics for the Evaluation of Endothelialization of Intravascular Devices,” Tissue Eng. 12, 3431-3438, 2006 (8 pages). |
| Gauvin, R. et al., “Dynamic Mechanical Stimulations Include Anisotropy and Improve the Tensile Properties of Engineered Tissues Produced Without Exogenous Scaffolding,” Acta. Biomater. 7, 3294-3301, 2011 (8 pages). |
| Kalejs, et al., “St. Jude Epic Heart Valve Bioprostheses Versus Native Human and Porcine Aortic Valves—Comparison of Mechanical Properties,” Interactive Cardiovascular and Thoracic Surgery 8 (2009) 553-557. |
| Kelm, J. M. et al., “Scaffold-Free Cell Delivery for Use in Regenerative Medicine,” Adv. Drug Deliv. Rev. 62, 753-764, 2010 (12 pages). |
| L'Heureux, N. et al., “A Completely Biological Tissue-Engineered Human Blood Vessel,” FASEB J. 12, 47-56, 1998 (10 pages). |
| Milleret, Vincent et al., “Tuning Electrospinning Parameters for Production of 3D-Fiber-Fleeces with Increased Porosity for Soft Tissue Engineering Applications,” Eur. Cell. Mater. 21, 286-303, 2011 (18 pages). |
| Schellenberg, Anne et al., “3D Non-Woven Polyvinylidene Fluoride Scaffolds: Fibre Cross Section and Texturizing Patterns Have Impact on Growth of Mesenchymal Stromal Cells,” PLOS ONE 9(4) e94353, 2014 (9 pages). |
| “Final Office Action,” for U.S. Appl. No. 15/272,747 dated Apr. 25, 2018 (12 pages). |
| “Final Office Action,” for U.S. Appl. No. 15/272,772 dated Jun. 5, 2018 (10 pages). |
| “International Preliminary Report on Patentability,” for PCT Application No. PCT/US2016/053680 dated Apr. 19, 2018 (8 pages). |
| “International Preliminary Report on Patentability,” for PCT Application No. PCT/US2016/053682 dated Apr. 19, 2018 (8 pages). |
| “International Preliminary Report on Patentability,” for PCT Application No. PCT/US2016/060449 dated May 24, 2018 (8 pages). |
| “Response to Final Office Action,” for U.S. Appl. No. 15/272,747 dated Apr. 25, 2018 and filed with the USPTO Jun. 18, 2018 (10 pages). |
| Number | Date | Country | |
|---|---|---|---|
| 20170128201 A1 | May 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62253225 | Nov 2015 | US |
